Valiant Laboratories Ltd Financials
Company Logo

Valiant Laboratories Ltd Financial Statement

Valiant Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue21.06
Operating Expense21.27
Net Profit-1.01
Net Profit Margin-4.80
Earning Per Share-0.23
EBIDTA-0.37
Effective Tax Rate-42.86

Valiant Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual182.05
Operating Expenses Annual190.46
Operating Profit Annual1.27
Interest Annual0.08
Depreciation1.95
Net Profit Annual0.34
Tax Annual-1.09

Valiant Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.38
Cash Flow from Operations48.78
Cash Flow from Investing-182.73
Cash Flow from Financing135.80
Cash Flow at the End2.23

Valiant Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-1.05
PBIT Margin (%)-2.13
PBT Margin (%)24.45
Net PROFIT Margin (%)0.19
Return On Networth / Equity (%)-1.70
Return On Networth /Employed (%)-1.68
Return On Assets (%)0.15
Total Debt / Equity (X)0.36
Asset Turnover Ratio (%)0.79

Valiant Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual31.61
Total Current Assets Annual209.27
Non Current Assets Annual115.46
Total Shareholders Funds Annual236.88
Total Assets Annual324.73

Valiant Laboratories Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-0.13

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Oct 8, 2024, Valiant Laboratories Ltd has a market capitalization of 632.63 Cr. Value Research classifies it as a Small-Cap company.
Yes, Valiant Laboratories Ltd is debt-free with a debt-to-equity ratio of 0.25.
In FY 2023 , Valiant Laboratories Ltd recorded a total revenue of approximately 182.05 Cr marking a significant milestone in the company's financial performance.
Valiant Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and -0.2% annually, respectively..
Valiant Laboratories Ltd's current PE ratio is 1860.68.
Valiant Laboratories Ltd's ROCE averaged 18.3% from the FY ending March 2022 to 2024, with a median of 23.7%. It peaked at 31.3% in March 2022, reflecting strong capital efficiency over the period..
Valiant Laboratories Ltd's latest EBIT is Rs. -0.67 Cr, surpassing the average EBIT of Rs. 26.50 Cr over the 5 years..